Related Experiment Video
Updated: Jan 7, 2026
12:05
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
Published on: November 3, 2018
12.2K
Tracking Cytopenias in FANCA-deficient Fanconi Anemia
Rochelle R Maxwell1, Tamar Berger1, Caroline S Jiang2
1Laboratory of Genome Maintenance, The Rockefeller University, New York, NY.
Medrxiv : the Preprint Server for Health Sciences
|December 25, 2025
Summary
Fanconi anemia (FA) is an inherited bone marrow failure disorder. This study shows that FANCA gene mutation type impacts disease progression and hematologic abnormalities in FA patients.
Area of Science:
- Hematology
- Genetics
- Oncology
Background:
- Fanconi anemia (FA) is an inherited disorder with bone marrow failure and cancer risk.
- Pathogenic variants in 23 genes cause FA; FANCA mutations are most common, affecting two-thirds of patients.
- Genotype-phenotype correlations for FANCA variants are often unclear.
Purpose of the Study:
- To describe the natural history of cytopenias in individuals with FANCA pathogenic variants.
- To correlate hematologic parameter decline with FANCA mutation subtypes.
- To assess the impact of androgen therapy on hematologic progression.
Main Methods:
- Retrospective analysis of blood cell counts in 139 individuals diagnosed with FA since 1995.
- Longitudinal follow-up of hematologic parameters.
- Correlation of cytopenias with FANCA mutation classifications.
Main Results:
- Most participants showed age-related declines in blood cell counts starting in childhood.
- Platelet counts declined earliest (median 8.2 years), followed by hemoglobin (median 10.7 years).
- Androgen therapy delayed hematologic decline; hypomorphic FANCA variants slowed progression.
Conclusions:
- Mutation type is crucial for predicting hematologic severity in FANCA-associated FA.
- This cohort provides a historical comparison for novel FA therapies.
- Understanding FANCA genotype-phenotype correlations aids in managing FA hematologic manifestations.
